Zonulin and Intestinal Permeability

Zonulin is a protein identified as the only known physiological regulator of intercellular tight junctions in the intestinal epithelium. Discovered by Alessio Fasano and colleagues at the University of Maryland in 2000, zonulin modulates the paracellular pathway — the space between epithelial cells — controlling what passes from the intestinal lumen into the bloodstream. When zonulin signaling is dysregulated, tight junctions open excessively, increasing intestinal permeability and allowing luminal contents (bacterial products, undigested proteins, toxins) to cross the epithelial barrier. This process is central to understanding both autoimmune pathogenesis and the mechanism of action of several gut-protective peptides.

Tight junction biology

The intestinal epithelium is a single cell layer that serves as the body's largest interface with the external environment, covering approximately 32 square meters in the adult human. This barrier must simultaneously absorb nutrients and exclude harmful substances — a challenge managed by tight junctions, the multiprotein complexes that seal the paracellular space between adjacent epithelial cells.

Tight junctions are composed of transmembrane proteins — claudins, occludin, and junctional adhesion molecules (JAMs) — that bridge the gap between cells, and intracellular scaffolding proteins — zonula occludens (ZO-1, ZO-2, ZO-3) — that anchor these transmembrane proteins to the actin cytoskeleton. The permeability of tight junctions is dynamically regulated rather than fixed; it can be adjusted in response to physiological needs (nutrient absorption) or pathological stimuli (infection, inflammation).

Zonulin: identity and mechanism

Zonulin was identified through research on the cholera toxin zonula occludens toxin (Zot), which opens intestinal tight junctions as part of cholera pathogenesis. Fasano's group reasoned that if a bacterial toxin could open tight junctions, the host likely possessed an endogenous analog — a molecule that physiologically regulated tight junction permeability. This search led to the identification of zonulin.

Subsequent molecular characterization identified zonulin as prehaptoglobin-2, the uncleaved precursor of haptoglobin-2. Haptoglobin is a well-known plasma protein that binds free hemoglobin, but its precursor form (prehaptoglobin-2) has the distinct ability to interact with intestinal epithelial receptors and modulate tight junctions before being cleaved to its mature form.

Signaling pathway

Zonulin modulates tight junctions through the following signaling cascade:

1. Zonulin binds to epidermal growth factor receptor (EGFR) and protease-activated receptor 2 (PAR2) on the apical surface of intestinal epithelial cells.
2. This activates phospholipase C, generating diacylglycerol (DAG) and inositol trisphosphate (IP3).
3. DAG activates protein kinase C alpha (PKCalpha), which phosphorylates tight junction proteins.
4. PKCalpha-mediated phosphorylation causes polymerization of intracellular actin filaments and displacement of ZO-1 from the tight junction complex.
5. The tight junction disassembles, increasing paracellular permeability.

This process is reversible — once the zonulin signal dissipates, tight junctions reassemble and barrier function is restored. Problems arise when zonulin signaling is chronically elevated, maintaining tight junctions in an open state.

Triggers of zonulin release

Gluten (gliadin)

Gliadin, the alcohol-soluble fraction of gluten, is the most studied trigger of zonulin release. When gliadin peptides interact with the chemokine receptor CXCR3 on the apical surface of intestinal epithelial cells, they stimulate zonulin release in a MyD88-dependent manner. This occurs in all individuals, not only those with celiac disease — the difference is that celiac patients have a genetically determined (HLA-DQ2/DQ8) immune response to gliadin that is amplified by the increased permeability, creating a pathological feedback loop.

Intestinal bacteria

Small intestinal bacterial overgrowth (SIBO) and exposure to pathogenic bacteria trigger zonulin release. This likely represents an innate defense mechanism — by opening tight junctions, the intestine flushes luminal contents and bacteria through increased fluid secretion, analogous to the diarrheal response in cholera.

Other triggers

Additional factors associated with increased zonulin and intestinal permeability include psychological stress (via CRH and mast cell activation), non-steroidal anti-inflammatory drugs (NSAIDs), alcohol, intensive exercise, and certain dietary components.

Zonulin in disease

Celiac disease

Celiac disease is the paradigmatic zonulin-associated condition. Patients show significantly elevated intestinal and serum zonulin levels compared to healthy controls. The pathological sequence is: gliadin triggers zonulin release, tight junctions open, gliadin fragments cross the barrier, tissue transglutaminase deamidates the gliadin peptides, and deamidated gliadin is presented to HLA-DQ2/DQ8-restricted T cells, triggering the adaptive immune response that damages the intestinal mucosa.

Type 1 diabetes

Elevated zonulin and increased intestinal permeability have been detected in patients with type 1 diabetes and in at-risk individuals before disease onset. In the BioBreeding diabetic rat model, zonulin upregulation and increased permeability precede the autoimmune destruction of pancreatic beta cells, and administration of a zonulin antagonist (larazotide) reduces diabetes incidence. Whether increased permeability is causal or a marker of early autoimmune activation in human type 1 diabetes remains debated.

Inflammatory bowel disease

Both Crohn's disease and ulcerative colitis are associated with increased intestinal permeability, though the relationship with zonulin specifically is less clear than in celiac disease. Barrier dysfunction in IBD involves multiple mechanisms beyond zonulin, including cytokine-mediated tight junction disruption (TNF-alpha, IFN-gamma) and epithelial cell apoptosis.

Other conditions

Elevated zonulin or increased intestinal permeability has been reported in irritable bowel syndrome (particularly post-infectious IBS), ankylosing spondylitis, multiple sclerosis, rheumatoid arthritis, and even neuropsychiatric conditions (autism spectrum disorder, schizophrenia). These associations are mostly correlational, and whether permeability changes are cause or consequence of disease in each case remains an area of investigation.

Measurement controversies

Zonulin measurement has been a significant source of confusion in the literature. The commercial ELISA kits most widely used to measure "zonulin" in serum have been shown to primarily detect complement C3 and properdin rather than prehaptoglobin-2 itself. A 2019 study by Scheffler and colleagues demonstrated that the most commonly used ELISA (Immundiagnostik) has poor specificity for the actual zonulin molecule.

This means that many published studies reporting "elevated zonulin" in various diseases may have been measuring a different protein entirely. More specific assays are needed, and results from older studies using commercial ELISAs should be interpreted with caution. The lactulose-mannitol permeability test remains the gold standard for directly assessing intestinal permeability, measuring the ratio of these two sugars in urine after oral ingestion.

Peptide interventions

Larazotide acetate (AT-1001)

Larazotide is a synthetic octapeptide derived from the structure of the Vibrio cholerae Zot toxin. It functions as a zonulin antagonist — it binds to the zonulin receptor and prevents zonulin from opening tight junctions. Larazotide is not systemically absorbed; it acts locally in the intestinal lumen.

Clinical trials for celiac disease have shown that larazotide reduces gluten-induced symptoms and permeability changes, though it does not fully prevent the immune response to gluten. In a phase 2b trial, larazotide 0.5 mg three times daily significantly reduced symptoms in celiac patients on a gluten-free diet who had persistent symptoms. A phase 3 trial has been conducted, and the drug has received FDA Fast Track designation for non-responsive celiac disease. Larazotide represents one of the most advanced peptide therapeutics in gastroenterology.

BPC-157

BPC-157 (Body Protection Compound-157) is a pentadecapeptide derived from a sequence in human gastric juice. In animal models, BPC-157 has demonstrated mucosal protection across the gastrointestinal tract, including protection against NSAID-induced, alcohol-induced, and stress-induced gut injury. Proposed mechanisms include stabilization of tight junction proteins, upregulation of growth factor receptors (EGFR, VEGFR2), and modulation of the nitric oxide system.

However, it is important to note that BPC-157 research consists almost entirely of preclinical animal studies, with no published controlled human trials as of this writing. Its specific effects on zonulin signaling have not been directly studied, though its broad gut-protective profile suggests potential relevance to intestinal barrier function.

Practical considerations

The concept of "leaky gut" has entered popular health discourse, often far outpacing the scientific evidence. While the role of intestinal permeability in celiac disease is well established, its causal role in many other conditions attributed to "leaky gut" remains unproven. Commercially available zonulin tests are of questionable specificity. Patients and clinicians should be cautious about over-interpreting zonulin measurements or attributing diverse symptoms to intestinal permeability without adequate diagnostic workup. The field would benefit from validated, specific biomarkers for intestinal permeability and from well-designed intervention trials testing whether reducing permeability actually improves disease outcomes in non-celiac conditions.